NCT02502578

Safety Study of CNT-01 in Patients With Idiopathic TGCV

Phase I/IIa Study of CNT-01 in Patients With Idiopathic Triglyceride Deposit

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Osaka University · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety and to examine the index of the efficacy after repeated dosing of CNT-01 in patients with idiopathic triglyceride deposit cardiomyovasculopathy.

Conditions

• Idiopathic Triglyceride Deposit Cardiomyovasculopathy

Interventions

Type	Name	Description
DRUG	CNT-01 500 mg capsule	After being informed about the study and potential risks, all patients giving written informed consent undergo screening tests to determine eligibility for study enrollment. On Day 1, patients who meet the eligibility criteria will start taking CNT-01 500mg orally three times daily for 14 days. On Day 15, patients will take CNT-01 500 mg only once after blood drawing.

Timeline

• Start date: 2015-09-01
• Primary completion: 2016-06-01
• First posted: 2015-07-20
• Last updated: 2016-09-28

Locations

1 site across 1 country: Japan